<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medalphabet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский алфавит</journal-title><trans-title-group xml:lang="en"><trans-title>Medical alphabet</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2078-5631</issn><issn pub-type="epub">2949-2807</issn><publisher><publisher-name>ООО «Альфмед»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33667/2078-5631-2019-1-1(376)-53-58</article-id><article-id custom-type="elpub" pub-id-type="custom">medalphabet-935</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>Роль преконцепционной эндотелиальной дисфункции в развитии акушерских осложнений</article-title><trans-title-group xml:lang="en"><trans-title>Role ofpreconception endothelial dysfunction in development of obstetric complications</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кузнецова</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuznetsova</surname><given-names>I. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО «Первый Московский государственный медицинский университет имени И. М. Сеченова (Сеченовский университет)» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>First Moscow State Medical University n.a. I. M. Sechenov</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>10</day><month>01</month><year>2019</year></pub-date><volume>1</volume><issue>1</issue><issue-title>Современная гинекология</issue-title><fpage>53</fpage><lpage>58</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кузнецова И.В., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Кузнецова И.В.</copyright-holder><copyright-holder xml:lang="en">Kuznetsova I.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-alphabet.com/jour/article/view/935">https://www.med-alphabet.com/jour/article/view/935</self-uri><abstract><p>В статье освещены патогенетические механизмы формирования эндотелиальной дисфункции и ее роль в возникновении гестационных осложнений. Рассмотрены основные задачи прегравидарной подготовки пациентов с заболеваниями, ассоциированными с эндотелиальной дисфункцией. Подчеркивается актуальность раннего выявления факторов риска гестационных осложнений, обусловленных дисфункцией эндотелия, и описываются методы ее косвенной оценки. Приведен перечень мероприятий, направленных на предотвращение клинической реализации эндотелиальной дисфункции, и описаны возможности ее терапевтической коррекции.</p></abstract><trans-abstract xml:lang="en"><p>The article highlights the pathogenetic mechanisms of endothelial dysfunction formation and its role in the occurrence of gestational complications. The main tasks of the pregravid preparation of patients with diseases associated with endothelial dysfunction are considered. The relevance of early detection of risk factors for gestational complications caused by endothelial dysfunction is emphasized, and methods for its indirect assessment are described. A list of measures aimed at preventing the clinical implementation of endothelial dysfunction is given, and the possibilities of its therapeutic correction are described.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>эндотелиальная дисфункция</kwd><kwd>прегравидарная подготовка</kwd><kwd>осложнения беременности</kwd><kwd>преэклампсия</kwd><kwd>сахарный диабет</kwd><kwd>синдром поликистозных яичников</kwd><kwd>сулодексид</kwd></kwd-group><kwd-group xml:lang="en"><kwd>endothelial dysfunction</kwd><kwd>pregravid preparation</kwd><kwd>pregnancy complications</kwd><kwd>preeclampsia</kwd><kwd>diabetes mellitus</kwd><kwd>polycystic ovary syndrome</kwd><kwd>sulodexide</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Chatterjee Sh. Endothelial Mechanotransduction, Redox Signaling and the Regulation of Vascular Inflammatory Pathways. Front Physiol. 2018; 9: 524.</mixed-citation><mixed-citation xml:lang="en">Chatterjee Sh. Endothelial Mechanotransduction, Redox Signaling and the Regulation of Vascular Inflammatory Pathways. Front Physiol. 2018; 9: 524.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Daiber A, Steven S, Weber A, et al. Targeting vascular (endothelial) dysfunction. Br J Pharmacol 2017; 174 (12): 1591-1619.</mixed-citation><mixed-citation xml:lang="en">Daiber A, Steven S, Weber A, et al. Targeting vascular (endothelial) dysfunction. Br J Pharmacol 2017; 174 (12): 1591-1619.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Butt M, Dwivedi G, Blann A, Khair O, Lip GY. Endothelial dysfunction: Methods of assessment &amp; implications for cardiovascular diseases. Curr Pharm Des. 2010; 16: 3442-3454.</mixed-citation><mixed-citation xml:lang="en">Butt M, Dwivedi G, Blann A, Khair O, Lip GY. Endothelial dysfunction: Methods of assessment &amp; implications for cardiovascular diseases. Curr Pharm Des. 2010; 16: 3442-3454.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Gandley RE, Althouse A, Jeyabalan A, et al. Low Soluble Syndecan-1 Precedes Preeclampsia PLoS One. 2016; 11 (6): e0157608.</mixed-citation><mixed-citation xml:lang="en">Gandley RE, Althouse A, Jeyabalan A, et al. Low Soluble Syndecan-1 Precedes Preeclampsia PLoS One. 2016; 11 (6): e0157608.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Garrido-Gomez T, Ona K, Kapidzic M, et al. Severe pre-eclampsia is associated with alterations in cytotrophoblasts of the smooth chorion. Development2017; 144 (5): 767-777.</mixed-citation><mixed-citation xml:lang="en">Garrido-Gomez T, Ona K, Kapidzic M, et al. Severe pre-eclampsia is associated with alterations in cytotrophoblasts of the smooth chorion. Development2017; 144 (5): 767-777.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Макаров О. В., Волкова Е. В., Винокурова И. Н., Джохадзе Л. С. Лечение артериальной гипертензии у беременных. Проблемы репродукции. 2011; 6: 87-92.</mixed-citation><mixed-citation xml:lang="en">Макаров О. В., Волкова Е. В., Винокурова И. Н., Джохадзе Л. С. Лечение артериальной гипертензии у беременных. Проблемы репродукции. 2011; 6: 87-92.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Heimrath J, Paprocka M, Czekanski A, et al. Pregnancy-induced hypertension is accompanied by decreased number of circulating endothelial cells and circulating endothelial progenitor cells. Arch Immunol Ther Exp (Warsz). 2014; 62 (4): 353-356.</mixed-citation><mixed-citation xml:lang="en">Heimrath J, Paprocka M, Czekanski A, et al. Pregnancy-induced hypertension is accompanied by decreased number of circulating endothelial cells and circulating endothelial progenitor cells. Arch Immunol Ther Exp (Warsz). 2014; 62 (4): 353-356.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lash GE, Ansari T, Bishof P. IFPA Meeting 2008 Workshop Report. Placenta 2009; 30 (Suppl A): S4-14.</mixed-citation><mixed-citation xml:lang="en">Lash GE, Ansari T, Bishof P. IFPA Meeting 2008 Workshop Report. Placenta 2009; 30 (Suppl A): S4-14.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Myatt L, Muralimanoharan S, Maloyan A. Effect of preeclampsia on placental function: influence of sexual dimorphism, microRNA’s and mitochondria. Adv Exp Med Biol 2014; 814: 133-146.</mixed-citation><mixed-citation xml:lang="en">Myatt L, Muralimanoharan S, Maloyan A. Effect of preeclampsia on placental function: influence of sexual dimorphism, microRNA’s and mitochondria. Adv Exp Med Biol 2014; 814: 133-146.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Possomato-Vieira JS, Khalil RA. Mechanisms of Endothelial Dysfunction in Hypertensive Pregnancy and Preeclampsia. Adv Pharmacol 2016; 77: 361-431.</mixed-citation><mixed-citation xml:lang="en">Possomato-Vieira JS, Khalil RA. Mechanisms of Endothelial Dysfunction in Hypertensive Pregnancy and Preeclampsia. Adv Pharmacol 2016; 77: 361-431.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Shi Z, Long W, Zhao C, et al. Comparative proteomics analysis suggests that placental mitochondria are involved in the development of pre-eclampsia. PLoS One 2013; 8 (5): e64351.</mixed-citation><mixed-citation xml:lang="en">Shi Z, Long W, Zhao C, et al. Comparative proteomics analysis suggests that placental mitochondria are involved in the development of pre-eclampsia. PLoS One 2013; 8 (5): e64351.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Ann Rev Pathol. 2010; 5:173-192.</mixed-citation><mixed-citation xml:lang="en">Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Ann Rev Pathol. 2010; 5:173-192.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Villa PM, Kajantie E, Raikkonen K, et al. Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials. BJOG. 2013; 120 (1): 64-74.</mixed-citation><mixed-citation xml:lang="en">Villa PM, Kajantie E, Raikkonen K, et al. Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials. BJOG. 2013; 120 (1): 64-74.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Доброхотова Ю. Э., Боровкова Е. И. Прегравидарная подготовка: цели, задачи, возможности. Эффективная фармакотерапия 2017; 13: 14-18.</mixed-citation><mixed-citation xml:lang="en">Доброхотова Ю. Э., Боровкова Е. И. Прегравидарная подготовка: цели, задачи, возможности. Эффективная фармакотерапия 2017; 13: 14-18.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Moos MK, Dunlop AL, Jack BW, et al. Healthier women, healthier reproductive outcomes: recommendations for the routine care of all women of reproductive age. Am J Obstet Gynecol2008; 199 (6): S280-S289.</mixed-citation><mixed-citation xml:lang="en">Moos MK, Dunlop AL, Jack BW, et al. Healthier women, healthier reproductive outcomes: recommendations for the routine care of all women of reproductive age. Am J Obstet Gynecol2008; 199 (6): S280-S289.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Mazza D, Chapman A, Michie S. Barriers to the implementation of preconception care guidelines as perceived by general practitioners: a qualitative study. BMC Health Serv Res 2013; 13: 36.</mixed-citation><mixed-citation xml:lang="en">Mazza D, Chapman A, Michie S. Barriers to the implementation of preconception care guidelines as perceived by general practitioners: a qualitative study. BMC Health Serv Res 2013; 13: 36.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Sprung VS, Atkinson G, Cuthbertson DJ, et al. Endothelial function measured using flow-mediated dilation in polycystic ovary syndrome: A meta-analysis of the observational studies. Clin Endocrinol (Oxf) 2013; 78: 438-46.</mixed-citation><mixed-citation xml:lang="en">Sprung VS, Atkinson G, Cuthbertson DJ, et al. Endothelial function measured using flow-mediated dilation in polycystic ovary syndrome: A meta-analysis of the observational studies. Clin Endocrinol (Oxf) 2013; 78: 438-46.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Moran LJ, Cameron JD, Strauss BJ, Teede HJ. Vascular function in the diagnostic categories of polycystic ovary syndrome. Hum Reprod. 2011; 26: 2192-2199.</mixed-citation><mixed-citation xml:lang="en">Moran LJ, Cameron JD, Strauss BJ, Teede HJ. Vascular function in the diagnostic categories of polycystic ovary syndrome. Hum Reprod. 2011; 26: 2192-2199.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Palomba S, Falbo A, Giallauria F, et al. Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome. Diabetes Care 2010; 33: 246-251.</mixed-citation><mixed-citation xml:lang="en">Palomba S, Falbo A, Giallauria F, et al. Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome. Diabetes Care 2010; 33: 246-251.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Rajendran S, Willoughby SR, Chan WP, et al. Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects. Atherosclerosis. 2009; 204: 509-514.</mixed-citation><mixed-citation xml:lang="en">Rajendran S, Willoughby SR, Chan WP, et al. Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects. Atherosclerosis. 2009; 204: 509-514.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Toulis KA, Goulis DG, Mintziori G, Kintiraki E, Eukarpidis E, Mouratoglou SA, et al. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update. 2011; 17: 741-760.</mixed-citation><mixed-citation xml:lang="en">Toulis KA, Goulis DG, Mintziori G, Kintiraki E, Eukarpidis E, Mouratoglou SA, et al. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update. 2011; 17: 741-760.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010; 95: 2038-2049.</mixed-citation><mixed-citation xml:lang="en">Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010; 95: 2038-2049.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Pepene CE. Evidence for visfatin as an independent predictor of endothelial dysfunction in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2012; 76: 119-25.</mixed-citation><mixed-citation xml:lang="en">Pepene CE. Evidence for visfatin as an independent predictor of endothelial dysfunction in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2012; 76: 119-25.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Sprung VS, Jones H, Pugh CJ, et al. Endothelial dysfunction in hyperandrogenic polycystic ovary syndrome is not explained by either obesity or ectopic fat deposition. Clin Sci (Lond) 2014; 126:67-74.</mixed-citation><mixed-citation xml:lang="en">Sprung VS, Jones H, Pugh CJ, et al. Endothelial dysfunction in hyperandrogenic polycystic ovary syndrome is not explained by either obesity or ectopic fat deposition. Clin Sci (Lond) 2014; 126:67-74.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018; 17: о121.</mixed-citation><mixed-citation xml:lang="en">Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018; 17: о121.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Muniyappa R, Sowers JR. Roles of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord. 2013; 14: 5-12.</mixed-citation><mixed-citation xml:lang="en">Muniyappa R, Sowers JR. Roles of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord. 2013; 14: 5-12.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang X, McGeoch SC, Johnstone AM, et al. Platelet-derived micropar- ticle count and surface molecule expression differ between subjects with and without type 2 diabetes, independently of obesity status. J Thromb Thrombolysis. 2014;37:455-63.</mixed-citation><mixed-citation xml:lang="en">Zhang X, McGeoch SC, Johnstone AM, et al. Platelet-derived micropar- ticle count and surface molecule expression differ between subjects with and without type 2 diabetes, independently of obesity status. J Thromb Thrombolysis. 2014;37:455-63.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Li H, Li H, Bao Y, Zhang X, Yu Y. Free fatty acids induce endothelial dysfunction and activate protein kinase C and nuclear factor-kB pathway in rat aorta. Int J Cardiol 2011; 152 (2): 218-224.</mixed-citation><mixed-citation xml:lang="en">Li H, Li H, Bao Y, Zhang X, Yu Y. Free fatty acids induce endothelial dysfunction and activate protein kinase C and nuclear factor-kB pathway in rat aorta. Int J Cardiol 2011; 152 (2): 218-224.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Mathew M, Tay E, Cusi K. Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects. Cardiovasc Diabetol2010; 9: 9.</mixed-citation><mixed-citation xml:lang="en">Mathew M, Tay E, Cusi K. Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects. Cardiovasc Diabetol2010; 9: 9.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Kanasaki K, Palmsten K, Sugimoto H, et al. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature. 2008; 453 (7198): 1117-1121.</mixed-citation><mixed-citation xml:lang="en">Kanasaki K, Palmsten K, Sugimoto H, et al. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature. 2008; 453 (7198): 1117-1121.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Bain E, Wilson A, Tooher R, Gates S, Davis LJ, Middleton P. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev. 2014; 2: CD 001689.</mixed-citation><mixed-citation xml:lang="en">Bain E, Wilson A, Tooher R, Gates S, Davis LJ, Middleton P. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev. 2014; 2: CD 001689.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Royal College of Obstetricians and Gynaecologist. Reducing the risk of venous Thromboembolism during Pregnancy and the Puerperium Green-to Guideline No. 37a, 2015; 40p.</mixed-citation><mixed-citation xml:lang="en">Royal College of Obstetricians and Gynaecologist. Reducing the risk of venous Thromboembolism during Pregnancy and the Puerperium Green-to Guideline No. 37a, 2015; 40p.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Российское общество акушеров-гинекологов. Анестезия и интенсивная терапия у пациенток, получающих антикоагулянты для профилактики и лечения венозных тромбоэмболических осложнений в акушерстве. Клинические рекомендации (протокол лечения) МЗ РФ, 2018; 47 с.</mixed-citation><mixed-citation xml:lang="en">Российское общество акушеров-гинекологов. Анестезия и интенсивная терапия у пациенток, получающих антикоагулянты для профилактики и лечения венозных тромбоэмболических осложнений в акушерстве. Клинические рекомендации (протокол лечения) МЗ РФ, 2018; 47 с.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Chighizola CB, Ubiali T, Meroni PL. Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management - An Insight into Future Approaches. J Immunol Res 2015; 2015: 951424.</mixed-citation><mixed-citation xml:lang="en">Chighizola CB, Ubiali T, Meroni PL. Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management - An Insight into Future Approaches. J Immunol Res 2015; 2015: 951424.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Hoppensteadt DA, Fareed J. Pharmacological profile of sulodexide. Int Angiol 2014; 33 (3): 229-235.</mixed-citation><mixed-citation xml:lang="en">Hoppensteadt DA, Fareed J. Pharmacological profile of sulodexide. Int Angiol 2014; 33 (3): 229-235.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Coccheri S, Mannello F. Development and use of sulodexide in vascular diseases: implications for treatment. Drug Des Devel Ther. 2013; 8: 49-65.</mixed-citation><mixed-citation xml:lang="en">Coccheri S, Mannello F. Development and use of sulodexide in vascular diseases: implications for treatment. Drug Des Devel Ther. 2013; 8: 49-65.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Masola V, Zaza G, Onisto M, et al. Glycosaminoglycans, proteoglycans and sulodexide and the endothelium: biological roles and pharmacological effects. Int Angiol. 2014; 33 (3): 243-254.</mixed-citation><mixed-citation xml:lang="en">Masola V, Zaza G, Onisto M, et al. Glycosaminoglycans, proteoglycans and sulodexide and the endothelium: biological roles and pharmacological effects. Int Angiol. 2014; 33 (3): 243-254.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Karthikeyan VJ, Lip GY. Endothelial damage/ dysfunction and hypertension in pregnancy. Front Biosci. (Elite Ed). 2011; 1 (3): 1100-1108.</mixed-citation><mixed-citation xml:lang="en">Karthikeyan VJ, Lip GY. Endothelial damage/ dysfunction and hypertension in pregnancy. Front Biosci. (Elite Ed). 2011; 1 (3): 1100-1108.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">LaMarca B. Endothelial dysfunction; an important mediator in the Pathophysiology of Hypertension during Preeclampsia. Minerva Ginecol2012; 64 (4): 309-320.</mixed-citation><mixed-citation xml:lang="en">LaMarca B. Endothelial dysfunction; an important mediator in the Pathophysiology of Hypertension during Preeclampsia. Minerva Ginecol2012; 64 (4): 309-320.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Li T, Liu X, Zhao Z, et al. Sulodexide recovers endothelial function through reconstructing glycocalyx in the balloon-injury rat carotid artery model. Oncotarget2017; 8 (53): 91350-91361.</mixed-citation><mixed-citation xml:lang="en">Li T, Liu X, Zhao Z, et al. Sulodexide recovers endothelial function through reconstructing glycocalyx in the balloon-injury rat carotid artery model. Oncotarget2017; 8 (53): 91350-91361.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Eskens BJM, Vink H, VanTeeffelen. Improvement of Insulin Reistance in Diet-Induced Obese Mice by Sulodexide, an Endothelial Glycocalyx Mimetic. J Endocrinol Diabetes Obes 2014; 2 (2): 1027.</mixed-citation><mixed-citation xml:lang="en">Eskens BJM, Vink H, VanTeeffelen. Improvement of Insulin Reistance in Diet-Induced Obese Mice by Sulodexide, an Endothelial Glycocalyx Mimetic. J Endocrinol Diabetes Obes 2014; 2 (2): 1027.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Broekhuizen LN, Lemkes BA, Mooij HL, et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 2010; 53 (12): 2646-2655.</mixed-citation><mixed-citation xml:lang="en">Broekhuizen LN, Lemkes BA, Mooij HL, et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 2010; 53 (12): 2646-2655.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Gabryel B, Jarzabek K, Machnik G, et al. Superoxide dismutase 1 and glutathione peroxidase 1 are involved in the protective effect of sulodexide on vascular endothelial cells exposed to oxygen-glucose deprivation. Microvasc. Res2015; 103:26-35.</mixed-citation><mixed-citation xml:lang="en">Gabryel B, Jarzabek K, Machnik G, et al. Superoxide dismutase 1 and glutathione peroxidase 1 are involved in the protective effect of sulodexide on vascular endothelial cells exposed to oxygen-glucose deprivation. Microvasc. Res2015; 103:26-35.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Попова Т.А., Перфилова В. Н., Жакупова Г. А. и соавт. Влияние сулодексида на функциональное состояние митохондрий плаценты самок крыс с экспериментальной преэклампсией. Биомедицинская химия 2016; 62 (5): 572-576.</mixed-citation><mixed-citation xml:lang="en">Попова Т.А., Перфилова В. Н., Жакупова Г. А. и соавт. Влияние сулодексида на функциональное состояние митохондрий плаценты самок крыс с экспериментальной преэклампсией. Биомедицинская химия 2016; 62 (5): 572-576.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Федоренко А. В., Дикке Г. Б. Плацентарная недостаточность у беременных с гестационной артериальной гипертензией и патогенетический подход к ее профилактике. Фарматека 2015; 3.</mixed-citation><mixed-citation xml:lang="en">Федоренко А. В., Дикке Г. Б. Плацентарная недостаточность у беременных с гестационной артериальной гипертензией и патогенетический подход к ее профилактике. Фарматека 2015; 3.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Olde Engberink RH, Rorije NM, Lambers Heerspink HJ, et al. The blood pressure lowering potential of sulodexide - a systematic review and meta-analysis. Br J Clin Pharmacol. 2015; 80 (6): 1245-1253.</mixed-citation><mixed-citation xml:lang="en">Olde Engberink RH, Rorije NM, Lambers Heerspink HJ, et al. The blood pressure lowering potential of sulodexide - a systematic review and meta-analysis. Br J Clin Pharmacol. 2015; 80 (6): 1245-1253.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Iozza I, Cianci S, Di Natale A, et al. Update on systemic lupus erythematosus pregnancy. J Prenat Med 2010; 4 (4): 67-73.</mixed-citation><mixed-citation xml:lang="en">Iozza I, Cianci S, Di Natale A, et al. Update on systemic lupus erythematosus pregnancy. J Prenat Med 2010; 4 (4): 67-73.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Щербаков А. Ю., Меликова Т. А. Мониторинг эффективности применения натурального антикоагулянта сулодексид у беременных с аутоиммунным гипертиреозом на фоне гипергомоцистеинемии. Патология. 2017; 14 (39): 57-56.</mixed-citation><mixed-citation xml:lang="en">Щербаков А. Ю., Меликова Т. А. Мониторинг эффективности применения натурального антикоагулянта сулодексид у беременных с аутоиммунным гипертиреозом на фоне гипергомоцистеинемии. Патология. 2017; 14 (39): 57-56.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of CVD in women - 2011 update. A guideline from the American Heart Association. Circulation 2011; 123 (11): 1243-1262.</mixed-citation><mixed-citation xml:lang="en">Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of CVD in women - 2011 update. A guideline from the American Heart Association. Circulation 2011; 123 (11): 1243-1262.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
